Loading company
Beta Bionics, Inc.
BBNX · Nasdaq · ·
Next earnings: October 27, 2026
$19.43-5.4%Sep 29 close
- 1M
- -1.5%
- 6M
- +97.1%
- 1Y
- -2.2%
BBNX · Nasdaq · ·
Next earnings: October 27, 2026
$19.43-5.4%Sep 29 close
Beta Bionics, Inc. is scheduled to report next on October 27, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $32M | $23.2M | +37.76% |
| Profit | -$23.4M | -$16.9M | -38.73% |
| Profit per share | -$0.53 | -$0.39 | -35.90% |
| Free Cash Flow | -$15.7M | -$15.4M | -1.87% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Beta Bionics, Inc.’s Item 2.02 8-K filed July 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Beta Bionics, Inc. has no earnings call transcript available.